Skip to main content

Advertisement

SpringerLink
Log in

Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients

  • Glaucoma
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

We aimed to investigate the effects of a single 1-mg injection of intravitreal bevacizumab on iris vessels in neovascular glaucoma (NVG) patients.

Methods

Twenty-two surgically resected irises from glaucoma patients were obtained during trabeculectomy. Eight were from patients with NVG who received a 1-mg injection of intravitreal bevacizumab (IVB) before glaucoma surgery, eight were from patients with primary open-angle glaucoma (POAG), and six were from patients with NVG who were not administered IVB. The collected iris specimens were compared after immunohistochemical staining with anti-CD34 monoclonal antibodies and anti-VEGF monoclonal antibody, and the percentage of CD34-positive and VEGF-positive regions in the total area of the specimens from the three groups was compared.

Results

The difference in the CD34-positive area between all groups was statistically significant (p = 0.0061, Kruskal–Wallis test). There was no significant difference in the CD34-positive area between the NVG with IVB group and the POAG group (p = 0.3017, Mann–Whitney U test with Bonferroni correction). The POAG group had significantly fewer CD34-positive regions than the NVG without IVB group (p = 0.0019, Mann–Whitney U test with Bonferroni correction). Many vessels remained in the iris stroma, and there was no significant difference in the CD34-positive area between the NVG with IVB and NVG without IVB groups (p = 0.0357, Mann–Whitney U test with Bonferroni correction). The ratio of the length of CD34 expression on the iris surface in the NVG without IVB group was significantly longer than that in the NVG with IVB group (p = 0.0002, Mann–Whitney U test). The difference in VEGF expression between all groups was statistically significant (p = 0.04, Kruskal–Wallis test). There was no significant difference between the NVG with IVB group and the NVG without IVB group (p = 0.7963 Mann–Whitney U test with Bonferroni correction). The frequency of hyphema and fibrin formation in the anterior chamber 1 day after surgery between the two NVG groups was not statistically significant.

Conclusion

A single intravitreal dose of IVB at 1 mg/0.04 ml to eyes with rubeotic glaucoma reduced the neovascularization in the human iris surface, but could not eliminate completely neovascularization in iris stroma. This finding implies that the prevention of hyphema and fibrin formation based on the slit-lamp examination can not be predicted, even if neovascularization in iris surface seems to be eliminated by a single dose of IVB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E (2000) Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 41:1649–1656

    CAS  PubMed  Google Scholar 

  2. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B (2004) Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10:2584–2586

    Article  CAS  PubMed  Google Scholar 

  3. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  4. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245(1):68–73

    Article  CAS  PubMed  Google Scholar 

  5. Vatavuk Z, Bencic G, Mandic Z (2007) Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol 17:269–271

    CAS  PubMed  Google Scholar 

  6. Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE et al (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 38:233–237

    PubMed  Google Scholar 

  7. Mason JO 3rd, Albert MA Jr, Vail R (2006) Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26:356–357

    Article  PubMed  Google Scholar 

  8. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352–354

    Article  PubMed  Google Scholar 

  9. Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26:354–356

    Article  PubMed  Google Scholar 

  10. Grisanti S, Bieste S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU (2006) Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142:158–160

    Article  CAS  PubMed  Google Scholar 

  11. Iliev ME, Domingo D, Wolf-Schnurrbursch U, Wolf S, Sarra G (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142:1054–1056

    Article  CAS  PubMed  Google Scholar 

  12. Jonas JB, Spandau UH, Schlichtenbrede F (2007) Intravitreal bevacizumab for filtering surgery. Opthalmic Res 39:121–122

    Article  CAS  Google Scholar 

  13. Kahook MY, Schuman JS, Noecker RJ (2006) Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37:144–146

    PubMed  Google Scholar 

  14. Mason JO 3rd, Albert MA Jr, Mays A, Vail R (2006) Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26:839–841

    Article  PubMed  Google Scholar 

  15. Silva PJ, Jorge R, Alves CR, Rodrigues ML, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84:556–557

    Article  Google Scholar 

  16. Yazdani S, Hendi K, Pakravan M (2007) Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 16:437–439

    Article  PubMed  Google Scholar 

  17. Witmer AN, van Blijswijk BC, van Noorden CJ, Vrensen GF, Schlingemann RO (2004) In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem 52:39–52

    CAS  PubMed  Google Scholar 

  18. Iriyama A, Chen YN, Tamaki Y, Yanagi Y (2007) Effect of anti VEGF-antibody on retinal ganglion cells in rats. Br J Opthalmol 91:1230–1233

    Article  Google Scholar 

  19. Bakri SJ, Cameron D, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162–164

    Article  CAS  PubMed  Google Scholar 

  20. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Opthalmol 143:995–1002

    Article  CAS  Google Scholar 

  21. Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC (2001) Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 108:1767–1778

    Article  CAS  PubMed  Google Scholar 

  22. Miki A, Oshima Y, Otori Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Opthalmol 92:1431–1433

    Article  CAS  Google Scholar 

  23. Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S (2006) Trabeculectomy with itomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica 220(6):383–388

    Article  CAS  PubMed  Google Scholar 

  24. Elgin U, Berker N, Batman A, Simsek T, Cankaya B (2006) Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma 15(5):466–470

    Article  PubMed  Google Scholar 

  25. Kiuchi Y, Nakae K, Saito Y, Ito S, Ito N (2006) Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 244(12):1627–1632

    Article  PubMed  Google Scholar 

  26. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F et al (2008) Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571–1580

    Article  PubMed  Google Scholar 

  27. Kaempf S, Johnen S, Salz AK, Weinberger A, Walter P, Thumann G (2008) Effects of bevacizumab (Avastin) on retinal cells in organotypic culture. Invest Ophthalmol Vis Sci 49(7):3164–3171

    Article  PubMed  Google Scholar 

  28. Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K (2010) Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmologica 88(1):96–102

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan

    Yosuke Sugimoto, Hideki Mochizuki, Hideaki Okumichi, Michiya Takamatsu & Yoshiaki Kiuchi

  2. Department of Otorhinolaryngology and Head and Neck Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan

    Masaya Takumida

  3. Department of Anatomy and Histology, Graduate School of Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan

    Seiichi Kawamata

Authors
  1. Yosuke Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Mochizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideaki Okumichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaya Takumida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michiya Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seiichi Kawamata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshiaki Kiuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yosuke Sugimoto.

Additional information

Conflicts of interest

The authors have no conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sugimoto, Y., Mochizuki, H., Okumichi, H. et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 248, 1601–1609 (2010). https://doi.org/10.1007/s00417-010-1406-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1406-x

Keywords

Search

Navigation